CRISPR Gene Editing Market Size is projected to reach USD 14.80 Billion by 2030, growing at a CAGR of 29.80%: Straits Research
August 01, 2022 12:40 ET
|
Straits Research
New York, United States, Aug. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Gene Editing, also called genome editing, modifies an organism's DNA. This method replaces, adds, or removes genetic material from...
South Texans can participate in massive, national health program to change the future of healthcare
July 25, 2022 08:30 ET
|
BioBridge Global
SAN ANTONIO, July 25, 2022 (GLOBE NEWSWIRE) -- South Texas Blood & Tissue has partnered with the National Institutes of Health’s All of Us Research Program, to recruit and engage participants in...
New Gadolinium-Free MRI Contrast Agent Advances Safer Patient Care
June 13, 2022 10:00 ET
|
Reveal Pharmaceuticals
CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Contrast agents used in MRI scans to improve the clarity of imaging for diagnostic accuracy, accumulate in the brain and body of every patient,...
Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
June 01, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National...
Inherent Biosciences, Inc. Awarded NIH SBIR Phase I Grant to Commercialize Innovative Diagnosis of Non-Obstructive Azoospermia (The Most Severe Form of Sperm Dysfunction)
April 13, 2022 09:11 ET
|
Inherent Biosciences Inc
SALT LAKE CITY, April 13, 2022 (GLOBE NEWSWIRE) -- Inherent Biosciences, a biotechnology company pioneering epigenetic medicine, today announced an award from the National Institute of Child Health...
Co-developer of COVID-19 Vaccine Joins GreenLight Advisory Board
March 29, 2022 13:04 ET
|
GreenLight Biosciences
BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC, a biotechnology company focused on RNA research, product design, development, and manufacturing for human, animal, and plant...
SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations
March 02, 2022 06:00 ET
|
SAB Biotherapeutics, Inc.
NIH is closing enrollment in its ACTIV-2 trial due to low Omicron-related COVID-19 hospitalization and death rates that have made the current study design statistically unworkable SAB-185 had advanced...
BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022
January 24, 2022 15:52 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
Enterin and Their Collaborators at NIH Announce That Alpha-Synuclein, the Culprit in Parkinson's Disease, is Core and Central to Normal Immune Function
January 11, 2022 15:00 ET
|
Enterin Inc.
PHILADELPHIA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program
November 04, 2021 07:00 ET
|
reMYND
Press Release reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program Leuven Belgium, 4 November 2021: reMYND NV, a clinical stage company...